Sinopharm Group stock
1099.HKHKSESinopharm Group Co. Ltd., HealthcareISIN CNE100000FN7
58Score 58 out of 100, Neutral
Price and trend
57 / 100
Price history
−22% in one yearThe chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.4% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 73).
The price is 24% below its 52-week high. Largest decline in 17 years: 67% (April 2018 to October 2022).
Chart figures for advanced users
- SMA 50$1.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.28
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)73
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.87
- The lowest closing price of the last twelve months.
- Resistance$2.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sinopharm Group Co. Ltd. belongs to the Medical (Distribution) industry (China) and, with a market value of $6.66B, is number 6 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $86.22B (down 1.6% year on year) and earnings of $1.07B (up 1.5%).
- MEQIRI Score 58 out of 100 (Neutral): rank 295 of 714 in Healthcare, median 53.
Show more
- The P/E is 6.3 (Healthcare sector median 32.6, own median of recent years 7.4).
- Our model puts fair value at $7.22, with the price 70% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 265% of earnings over the last 12 months.Fundamentals 82
- Below fair valuePrice 70% below the fair value of $7.22.Valuation 96
- High dividend yieldDividend yield 4.71%, Healthcare sector median 1.37%.
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are valuation and fundamentals, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $5.15 and expensive above $12.03 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $3.41 (cash-flow model) and $11.02 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $7.09, at 11.6% it would be $7.36.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (32.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 1.4% on the twelve months before. Revenue has grown strongly since 2006, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 7%, operating 3%, net 1%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 19 Mar 2027in 127 days
- Last reported
- 20 Aug 2026EPS reported 1.26 (expected 1.26)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 23 Oct 2026.
- Earnings per share
- 2.36+0.5%
- Revenue
- $88.61B+0.2%
- Earnings per share
- 2.5+0.3%
- Revenue
- $91.31B+0.1%
MEQIRI has stored the estimates since 23 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Sinopharm Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- CencoraCOR $66.77B74
- Cardinal HealthCAH $64.13B69
- Henry ScheinHSIC $9.77B66
- Shanghai Pharmaceuticals Holding601607.SS $9.01B53
- GalenicaGALE.SW $5.42B60
- AmplifonAMP.MI $3.68B49
- Asker Healthcare GroupASKER.ST $2.87B61
- Sopharma ADSPH.WA $1.9B57
ETFs that hold Sinopharm Group
Held by 45 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Edge MSCI EM Value Factor UCITS ETF5MVL | 0.26% | 0.40% | €1.48B |
| Franklin EM Multi-Factor Equity UCITS ETFFLXE | 0.21% | 0.30% | €102.26M |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.13% | 0.65% | €74.12M |
Show 5 more
| HSBC MSCI China UCITS ETFH4ZP | 0.12% | 0.28% | €865.21M |
| Franklin FTSE China UCITS ETFFLXC | 0.11% | 0.19% | €1.3B |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.10% | 0.30% | €134.65M |
| Invesco RAFI Emerging Markets Fundamental Value UCITS ETF6PSK | 0.07% | 0.49% | €85.48M |
| Avantis Emerging Markets Equity UCITS ETF USD AccAVEM | 0.07% | 0.35% | €277.45M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = HK$7.8456, $1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Sep 2016)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.